Kura Oncology Posts $13.9 Million Quarter, Buys Time to 2028

Kura Oncology (NASDAQ:KURA) reported third-quarter 2026 net product revenue of $13.9 million for KOMZIFTI, its drug for relapsed or refractory NPM1-mutated acute myeloid leukemia — a 53% increase over the prior quarter. The number is real, but it rests on a launch still measured in hundreds of prescriptions, not thousands, and management itself flagged where the evidence remains thin.

How fast is KOMZIFTI actually growing?

The quarter delivered approximately 150 new patient starts, up about 30% sequentially, and more than 420 total prescriptions, up 65%. Chief Commercial Officer Brian Powl attributed the faster growth in total prescriptions to a larger contribution from refills as the treated population expanded. A total of 170 accounts had prescribed the drug, up 40% from the prior quarter.

Kura maintained a majority share of menin inhibitor new patient starts in the approved population. Powl estimated that just under half of eligible patients currently receive a menin inhibitor — which means more than half do not, a gap that cuts both ways: opportunity for Kura, or a market that is converting slower than the category's advocates imply.

What did the claims data show — and what did it not?

In an available claims dataset, nearly half of KOMZIFTI patients received the drug alongside other approved agents, primarily venetoclax and azacitidine or FLT3 inhibitors. Powl noted that Kura's commercial teams promote the drug only for its approved indication. The juxtaposition is notable; the company is not driving the combination use it will later need to prove.

Asked about treatment duration, Powl said the data were not yet mature enough for a full assessment. The company continues to guide to approximately six months of treatment. In plain words: the duration assumption that underpins revenue models remains an estimate, not a measurement.

What comes next on the clinical side?

Kura plans to present eight ziftomenib abstracts, including four oral presentations, at the upcoming American Society of Hematology meeting. Chief Medical Officer Mollie Leoni said the presentations will include the company's first clinical data combining ziftomenib with two FLT3 inhibitors.

• Leoni called frontline KOMET-007 results for ziftomenib, quizartinib and intensive chemotherapy "encouraging."
• KOMET-008, combining ziftomenib with gilteritinib, showed "encouraging activity and tolerability" in relapsed or refractory patients, including those previously treated with an FLT3 inhibitor.
• The call provided no numerical results for either combination.

The phase 3 KOMET-017 frontline program remains on track, with most global sites activated and enrollment progressing as planned. First top-line results from the intensive chemotherapy trial are expected in 2028 — two years out, and the pivotal test of the entire commercial thesis.

Is there a second drug behind ziftomenib?

Management said it reached alignment with the Food and Drug Administration on a potential path to full approval for darlifarnib in HRAS-mutant salivary gland cancer. Kura plans to submit an investigational new drug application by the end of 2026 and start a single-arm study of roughly 40 patients in the first half of 2027.

President and CEO Troy Wilson said: "Our priority is to grow our leadership in this setting while building the clinical evidence to support expansion into earlier treatment settings and combinations."

Leoni attributed the regulatory approach to the small patient population, unmet need and previously observed durable responses. Approval, however, would depend on the study and regulatory review — alignment with the FDA is a path, not a promise.

Kura is also evaluating darlifarnib with cabozantinib in renal cell carcinoma, with enrollment expected to finish in the first half of 2027 and initial data in the second half. A pancreatic cancer combination study with daraxonrasib is expected to begin dosing in the first half of 2027, with potential preliminary data later that year.

Can the balance sheet carry the plan?

Kura ended September with $492 million in cash, cash equivalents and short-term investments. Chief Financial Officer Jennifer Fulk said a financing agreement with Oberland Capital provides up to $300 million in potential funding. At closing, Kura received $50 million in debt funding and a $5 million equity investment; additional funding remains subject to conditions.

The agreement carries a capped single-digit royalty tied to U.S. KOMZIFTI net sales, with seven-year debt and principal due at maturity. That structure converts future drug sales into present liquidity — at a price Kura will pay for years.

The quarterly net loss narrowed 5% year over year to $70.2 million. Research and development expenses fell 2% to $67 million; selling, general and administrative expenses declined 8% to $30.2 million. Kura updated 2026 collaboration revenue guidance to $40 million to $45 million and maintained $90 million to $110 million for each of 2027 and 2028. Fulk said the guidance reflects non-cash accounting recognition rather than the timing of cash receipts.

She said September cash, subsequent financing proceeds and approximately $180 million in anticipated payments from partner Kyowa Kirin should fund the operating plan beyond the initial ziftomenib top-line results expected in 2028. The runway reaches the data; whether the data reward the wait is a question no guidance can answer.